Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

61.66USD
18 Jan 2017
Change (% chg)

$-0.20 (-0.32%)
Prev Close
$61.86
Open
$62.07
Day's High
$62.07
Day's Low
$61.32
Volume
1,618,492
Avg. Vol
2,327,712
52-wk High
$68.12
52-wk Low
$51.60

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and... (more)

Overall

Beta: 1.59
Market Cap(Mil.): $100,203.60
Shares Outstanding(Mil.): 1,625.10
Dividend: 0.64
Yield (%): 4.15

Financials

  ABBV.N Industry Sector
P/E (TTM): 16.59 29.57 30.46
EPS (TTM): 3.72 -- --
ROI: 11.74 15.39 14.82
ROE: 107.29 16.58 16.24

Investors in big pharma, biotech look to ride out Trump storm

NEW YORK Investors in large U.S. pharmaceutical and biotech companies are counting on strong dividends, reasonable stock valuations and new products to help ride out a storm of political uncertainty as the incoming Trump administration dives into healthcare policy.

13 Jan 2017

Investors in big pharma, biotech look to ride out Trump storm

NEW YORK, Jan 12 Investors in large U.S. pharmaceutical and biotech companies are counting on strong dividends, reasonable stock valuations and new products to help ride out a storm of political uncertainty as the incoming Trump administration dives into healthcare policy.

13 Jan 2017

AbbVie vows to keep drug price increases below 10 percent

AbbVie Inc Chief Executive Richard Gonzalez on Wednesday promised to keep all drug price increases in 2017 under 10 percent, becoming the third global drugmaker to publicly make that pledge.

12 Jan 2017

BRIEF-Abbvie sees 2017 adjusted EPS growth 13-15 percent

* Abbvie sees 2017 adjusted EPS growth of 13-15 percent - JP Morgan Healthcare Conference

11 Jan 2017

BRIEF-Zebra Biologics Inc. to collaborate with AbbVie to discover new antibody therapeutics

* Zebra Biologics Inc. to collaborate with AbbVie to discover new antibody therapeutics.

09 Jan 2017

BRIEF-Emergent Tech says Pure MHC, AbbVie to embark on research, license deal

* Emergent says Pure MHC, AbbVie will embark on research, license deal to discover peptide targets for use with t-cell receptor therapeutics in cancers Source text for Eikon: Further company coverage:

09 Jan 2017

BRIEF-Abbvie announces four new collaborations and investments with healthcare companies

* Abbvie Inc - announced four new collaborations and investments with healthcare companies Source text for Eikon: Further company coverage:

09 Jan 2017

BRIEF-AbbVie, Genomics Medicine and WuXi NextCODE announce Population Genomics alliance

* Abbvie - Co, Genomics Medicine Ireland, WuXi NextCODE announce Population Genomics alliance; financial terms were not disclosed Source text for Eikon: Further company coverage:

09 Jan 2017

BRIEF-AbbVie says announces high SVR(12) rates with 8 weeks of treatment with its investigational drug

* Eight weeks of treatment with abbvie's investigational, pan-genotypic, ribavirin-free regimen of glecaprevir/pibrentasvir (G/P) for chronic hepatitis C achieved high SVR rates in genotype 1 Japanese patients

09 Jan 2017

Clovis's ovarian cancer drug wins accelerated FDA approval

The U.S. Food and Drug Administration granted accelerated approval to Clovis Oncology Inc's ovarian cancer drug in patients with a specific gene mutation whose disease had advanced despite two or more rounds of chemotherapy.

20 Dec 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $114.70 -0.17
Pfizer Inc. (PFE.N) $32.03 -0.03
Novartis AG (NOVN.S) CHF71.45 -0.75
Merck & Co., Inc. (MRK.N) $61.17 -0.31
Roche Holding Ltd. (ROG.S) CHF233.30 -2.30
Roche Holding Ltd. (RO.S) CHF237.30 -1.40
Abbott Laboratories (ABT.N) $40.76 -0.14
Eli Lilly and Co (LLY.N) $77.53 +0.68
Sanofi SA (SASY.PA) €76.06 -0.44

Earnings vs. Estimates